参与了“国家重点研发计划”、“科技部重大新药创制专项”等项目的申报和研究工作。开发了可特异表达MANF的PD基因治疗候选药物，目前已进入非人灵长类生物安全性评价阶段。目前已发表SCI论文10余篇，其中以第一或共同第一作者发表SCI论文7篇。以此为基础获得2019年国家自然科学基金青年项目以及2021年度上海市同济医院优秀青年人才计划资助。参与获得2019年度上海医学科技奖青年奖。
Participated in the application and research work of "National Key R&D Program" and "National Major Scientific and Technological Special Project for Significant New Drugs Development". Developed a gene therapeutic drug of PD, which can specifically express MANF. This candidate is currently in the stage of biosafety evaluation in non-human primates. Published more than 10 SCI papers, among which 7 papers as first author or co-first author. Presided as principal investigator over one National Natural Science Foundation Youth Project and one Shanghai Tongji Hospital Outstanding Young Talents Program, respectively. Awarded the prize of 2019 Shanghai Young Medical Technology Award.
